This year’s conference focused on the events leading up to 2018 and the future of 340B. With all the change and uncertainty in the past year, action is necessary. Hospitals are seeing the effects of this upheaval and will need to ensure their voices are heard.

In late January, two studies were released that claim to either “prove” that the 340B Drug Pricing program is not helping patients the way it was intended, and/or that the Medicare reimbursement cuts recently implemented by CMS will be beneficial…

One large medical center has found a way to make the most of its 340B program, further establishing itself as a leading institution in the nation, by increasing its 340B-eligible prescription volume by more than 100 percent in a matter of months…

On December 29, 2017, the U.S. District Court for the District of Columbia granted the government’s motion to dismiss the lawsuit filed by the American Hospital Association and other hospital groups, which had sought to prevent the 340B program…

In a recent survey of hospital pharmacy executives conducted by Porter Research, 78% of respondents answered “yes” when asked, “Are you aware the Federal DEA agency has created a task force seeking to identify diversion fraud in hospitals…

On November 1, CMS issued a final ruling on the 340B Drug Pricing Program reimbursement cuts, which will reduce the reimbursements CMS offers to hospitals for drugs that qualify under the 340B program from 6 percent above sale price to 22.5…

With close to 25,000 health-system pharmacists from around the world in attendance, best practices in 340B and analytics were key topics of discussion at the ASHP Midyear Clinical Meeting this year. The meeting largely attracts system directors,…

On Wednesday, November 1, CMS issued its final Hospital Outpatient Prospective Payment System rule (the final rule was published in the Nov. 13 Federal Register). Part of the ruling includes the 340B Drug Pricing Program reimbursement cuts…

Cost of developing cancer drugs is unclear The variability in costs to develop drugs is astonishing. A report from the Tufts Center for the Study of Drug Development puts the total cost of developing a new drug and taking it to market at about…